Spots Global Cancer Trial Database for A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM
Official Title: A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma
Study ID: NCT04184050
Interventions
Study Description
Brief Summary: An open-label, Phase 1 study of HPN217 to assess the safety, tolerability and PK in patients with relapsed/ refractory multiple myeloma
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Mayo Clinic Arizona, Phoenix, Arizona, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
The University of Kansas Cancer Center, Fairway, Kansas, United States
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
University of Rochester James P Wilmot Cancer Institute, Rochester, New York, United States
OHSU, Portland, Oregon, United States
University of Washington - Seattle Cancer Center Alliance, Seattle, Washington, United States
Centre Hospitalier Universitaire De Nantes, Nantes, , France
Centre Hospitalier Universitaire de Poitiers, Poitiers, , France
Josep Carreras Leukaemia Research Institute, Barcelona, , Spain
Hospital Universitario Fundacion Jimenez Diaz (UAM-FJD), Madrid, , Spain
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
